Key Highlights
- $310 million acquisition enhances Hologic’s breast surgery technologies.
- Acquisition includes innovative products like Magseed®, Magtrace®, and Sentimag®.
- Expected to be dilutive in 2024, break even in 2025, and accretive thereafter.
Source: Business Wire
Notable Quotes
- “Endomag’s suite of solutions complements our existing breast surgery portfolio and will provide surgeons and radiologists with an expanded range of options to meet the individual needs of more patients undergoing critical breast cancer procedures,” – Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic
- “We are delighted to attract the strength and focus of Hologic to power the next phase of our growth,” – Eric Mayes, CEO at Endomagnetics Ltd (Endomag®)
SoHC's Take
The strategic acquisition of Endomag by Hologic, Inc. is not just a substantial financial investment but a significant step in advancing the standards of breast cancer care. This merger is poised to broaden the spectrum of surgical solutions available, potentially transforming the landscape of patient care in this critical area. With both companies sharing a deep commitment to enhancing women’s health, the integration of their expertise and technologies is expected to foster innovation and extend their reach in global markets, ensuring that newer, non-invasive technologies become more accessible. This move underscores Hologic’s focused strategy on expanding its footprint in the women’s health sector, particularly in breast cancer diagnostics and surgical interventions, aligning with its mission to drive better health outcomes.
